Outcomes in patients with spinal muscular atrophy and four or more SMN2 copies treated with onasemnogene abeparvovec: Findings from RESTORE

被引：0
|
作者：
Finkel, R. [1 ]
Benguerba, K. [2 ]
Reid, A. [3 ]
Raju, D. [4 ]
Faulkner, E. [4 ]
LaMarca, N. [4 ]
Servais, L. [5 ]
机构：
[1] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[2] Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland
[3] Novartis Global RWE Gene Therapies, London, England
[4] Novartis Gene Therapies Inc, Bannockburn, IL USA
[5] Univ Oxford, Oxford, England
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.073
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.37
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [41] Onasemnogene abeparvovec in spinal muscular atrophy : predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies
    Pane, Marika
    Berti, Beatrice
    Capasso, Anna
    Coratti, Giorgia
    Varone, Antonio
    D'Amico, Adele
    Messina, Sonia
    Masson, Riccardo
    Sansone, Valeria Ada
    Donati, Maria Alice
    Agosto, Caterina
    Bruno, Claudio
    Ricci, Federica
    Pini, Antonella
    Gagliardi, Delio
    Filosto, Massimiliano
    Corti, Stefania
    Leone, Daniela
    Palermo, Concetta
    Onesimo, Roberta
    De Sanctis, Roberto
    Ricci, Martina
    Bitetti, Ilaria
    Sframeli, Maria
    Dosi, Claudia
    Albamonte, Emilio
    Ticci, Chiara
    Brolatti, Noemi
    Bertini, Enrico
    Finkel, Richard
    Mercuri, Eugenio
    ECLINICALMEDICINE, 2023, 59
  • [42] Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec
    Matesanz, Susan E.
    Curry, Candace
    Gross, Brianna
    Rubin, Adam I.
    Linn, Rebecca
    Yum, Sabrina W.
    Kichula, Elizabeth A.
    JOURNAL OF CHILD NEUROLOGY, 2020, 35 (11) : 717 - 723
  • [43] Bulbar function for patients with spinal muscular atrophy type 1 following onasemnogene abeparvovec
    McGrattan, K.
    Shell, R.
    Hurst-Davis, R.
    Young, S. Dunaway
    O'Brien, E.
    Lavrov, A.
    Wallach, S.
    LaMarca, N.
    Reyna, S.
    Darras, B.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S85 - S85
  • [44] Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?
    Mueller-Felber, Wolfgang
    Vill, Katharina
    Schwartz, Oliver
    Glaeser, Dieter
    Nennstiel, Uta
    Wirth, Brunhilde
    Burggraf, Siegfried
    Roeschinger, Wulf
    Becker, Marc
    Durner, Juergen
    Eggermann, Katja
    Mueller, Christine
    Hannibal, Iris
    Olgemoeller, Bernd
    Schara, Ulrike
    Blaschek, Astrid
    Koelbel, Heike
    JOURNAL OF NEUROMUSCULAR DISEASES, 2020, 7 (02) : 109 - 117
  • [45] Natural history of spinal muscular atrophy patients with 3 and 4 copies of SMN2 gene - data from the national Spanish registry (CUIDAME)
    Aragon Gawinska, K.
    Fernandez Garcia, M.
    Nascimiento Osorio, A.
    Paradas, C.
    Sotoca, J.
    Povedano, M.
    Moreno, A.
    Henao, M.
    Gil, C.
    Rojas, R.
    Gomez Caravaca, M.
    Grimalt, M.
    Fernandez Torron, R.
    Jerico, I.
    Garcia Campos, O.
    Toledo Bravo de Laguna, L.
    Hervas, D.
    Tizzano, E.
    Vazquez Costa, J.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [46] SMN2 deletion in childhood-onset spinal muscular atrophy
    Cobben, JM
    de Visser, M
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 109 (03): : 246 - 246
  • [47] Risdiplam SMN2 splicing modulator Treatment of spinal muscular atrophy
    Chiriboga, C. A.
    DRUGS OF THE FUTURE, 2019, 44 (08) : 643 - 658
  • [48] Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
    Mailman, MD
    Heinz, JW
    Papp, AC
    Snyder, PJ
    Sedra, MS
    Wirth, B
    Burghes, AHM
    Prior, TW
    GENETICS IN MEDICINE, 2002, 4 (01) : 20 - 26
  • [49] Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
    Day, John W.
    Finkel, Richard S.
    Chiriboga, Claudia A.
    Connolly, Anne M.
    Crawford, Thomas O.
    Darras, Basil T.
    Iannaccone, Susan T.
    Kuntz, Nancy L.
    Pena, Loren D. M.
    Shieh, Perry B.
    Smith, Edward C.
    Kwon, Jennifer M.
    Zaidman, Craig M.
    Schultz, Meredith
    Feltner, Douglas E.
    Tauscher-Wisniewski, Sitra
    Ouyang, Haojun
    Chand, Deepa H.
    Sproule, Douglas M.
    Macek, Thomas A.
    Mendell, Jerry R.
    LANCET NEUROLOGY, 2021, 20 (04): : 284 - 293
  • [50] Treatments and Outcomes for Patients with Spinal Muscular Atrophy (SMA) Type 2: Findings from RESTORE Registry
    Raju, D.
    Servais, L.
    Benguerba, K.
    De Vivo, D.
    Kirschner, J.
    Mercuri, E.
    Muntoni, F.
    Proud, C.
    Tizzano, E.
    Quijano-Roy, S.
    Saito, K.
    Faulkner, E.
    LaMarca, N.
    Sun, R.
    Anderson, F.
    Finkel, R.
    ANNALS OF NEUROLOGY, 2022, 92 : S152 - S153
12345